TY - JOUR T1 - The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway JF - medRxiv DO - 10.1101/2021.08.01.21261449 SP - 2021.08.01.21261449 AU - Paul Tran AU - Sharad Purohit AU - Eileen Kim AU - Khaled bin Satter AU - Diane Hopkins AU - Kathleen Waugh AU - Fran Dong AU - Suna Onengut-Gumuscu AU - Stephen S. Rich AU - Marian Rewers AU - Jin-Xiong She Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/05/2021.08.01.21261449.abstract N2 - Objective Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis.Research design and methods The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC).Results Serum CCL-2 levels were significantly lower in both progressors (p=0.004) and non-progressors (p=0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively).Conclusions The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport for this work to JXS was provided by the National Institutes of Health (R21HD050196, R33HD050196, and 2RO1HD37800). SP was supported by Postdoctoral Fellowship (10-2006-792 and 3-2004-195) and Career Development Award (2-2011-153) from JDRF. PMHT was supported by NIH/NIDDK fellowship (F30DK121461). Diabetes Autoimmunity Study in the Young (MR, KW, and FD) is supported by the National Institutes of Health (R01 DK032493 and P30 DK116073) and Helmsley Charitable Trust (G-1901-03687). This research utilizes resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and JDRF and supported by U01 DK062418.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Colorado Multiple Institutional Review Board and the Augusta University Institutional Review Board approved all study protocols.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings from this study are openly available from Zenodo (https://zenodo.org/record/2615265#.YGs9GEhKjYk) and the GTEx portal (https://www.gtexportal.org/home/gene/CCR2). The T1DGC Immunochip summary statistics data and the CCL-2 serum DAISY data are available by request to the authors. ER -